Market Place
Sourcing Support
Longeveron Wins Chinese Patent for MSC Potency Assays
08 Apr 2026 //
GLOBENEWSWIRE
Longeveron To Present 2025 Financial Results, Host Conference
12 Mar 2026 //
GLOBENEWSWIRE
Longeveron Finalizes $30M Private Placement
11 Mar 2026 //
GLOBENEWSWIRE
Longeveron Announces Private Placement Of Up To $30 Million
10 Mar 2026 //
GLOBENEWSWIRE
Longeveron Publishes Phase 2b Stem Cell Study in Cell Stem Cell
25 Feb 2026 //
GLOBENEWSWIRE
Longeveron Names Stephen H. Willard as CEO
13 Feb 2026 //
GLOBENEWSWIRE
Longeveron Secures Japan Patent For Human Mesenchymal Stem Cell
29 Jan 2026 //
GLOBENEWSWIRE
Startup Health Taps Longeveron for Alzheimer`s Moonshot
29 Dec 2025 //
GLOBENEWSWIRE
Longeveron Secures U.S. Patent for FSD Stem Cell Therapy
17 Dec 2025 //
GLOBENEWSWIRE
Longeveron Cso And Cmo To Speak At Global (CVCT) Forum
03 Dec 2025 //
GLOBENEWSWIRE
Longeveron Receives Canadian Patent For Stem Cell Treatment
02 Dec 2025 //
GLOBENEWSWIRE
Longeveron Presents New MRI Biomarker Data On Neuroinflammation
01 Dec 2025 //
GLOBENEWSWIRE
Longeveron`s Laromestrocel Selected for CTAD 2025
19 Nov 2025 //
GLOBENEWSWIRE
Longeveron Secures U.S. Patent For Treating Aging-Related Frailty
12 Nov 2025 //
GLOBENEWSWIRE
Longeveron Unveils Q3 2025 Financials & Business Update
04 Nov 2025 //
GLOBENEWSWIRE
Longeveron to Host Call on November 4, 2025 for Q3 Result
28 Oct 2025 //
GLOBENEWSWIRE
Longeveron To Join 4Th ROTH Healthcare Opportunities Conference
06 Oct 2025 //
GLOBENEWSWIRE
George Paletta, Jr. Joins Longeveron Board Of Directors
01 Oct 2025 //
GLOBENEWSWIRE
Longeveron To Attend Arm`s Cell & Gene Meeting On The Mesa
22 Sep 2025 //
GLOBENEWSWIRE
Longeveron® Announces Key Leadership Updates
03 Sep 2025 //
GLOBENEWSWIRE
Longeveron® to Speak at HC Wainwright 27th Global Investment Meet
20 Aug 2025 //
GLOBENEWSWIRE
Longeveron® Reveals Q2 2025 Financial Results and Business Update
13 Aug 2025 //
GLOBENEWSWIRE
Longeveron Announces $17.5 Million Public Offering
08 Aug 2025 //
GLOBENEWSWIRE
Longeveron® to Report Q2 2025 Financials, Host Conference Call
05 Aug 2025 //
GLOBENEWSWIRE
Longeveron Licenses Stem Cell Tech for Cardiovascular Disease
21 Jul 2025 //
GLOBENEWSWIRE
Longeveron® Completes Enrollment of Laromestrocel Trial for HLHS
24 Jun 2025 //
GLOBENEWSWIRE
Longeveron® to Join H.C. Wainwright Neuro Perspectives Conference
09 Jun 2025 //
GLOBENEWSWIRE
Longeveron® to Report Q1 2025 Financial Results, Host Call
02 May 2025 //
GLOBENEWSWIRE
Longeveron: Positive Type B Meeting with U.S. FDA for Laromestrocel
20 Mar 2025 //
GLOBENEWSWIRE
Longeveron® to Present at the 37th Annual Roth Conference
05 Mar 2025 //
GLOBENEWSWIRE
Longeveron® announces WHO approval of "laromestrocel"
18 Feb 2025 //
GLOBENEWSWIRE
Longeveron to Present at Biotech Showcase 2025
18 Dec 2024 //
GLOBENEWSWIRE
Longeveron To Present At Emerging Growth Virtual Conference Dec 5
02 Dec 2024 //
GLOBENEWSWIRE
Longeveron® Announces Q3 2024 Financial Results & Business Update
12 Nov 2024 //
GLOBENEWSWIRE
Longeveron® Appoints Devin as Chief Technology Officer & SVP of CMC
11 Nov 2024 //
GLOBENEWSWIRE
Longeveron® to Report Q3 2024 Results on Nov 12
04 Nov 2024 //
GLOBENEWSWIRE
Longeveron Presents Lomecel-B™ Data for Alzheimer’s at CTAD24
29 Oct 2024 //
GLOBENEWSWIRE
Longeveron® Presents Lomecel-B™ Data in HLHS at CHSS Meeting
27 Oct 2024 //
GLOBENEWSWIRE
Longeveron Lomecel-B Data In Alzheimer`s Selected For CTAD24
14 Oct 2024 //
GLOBENEWSWIRE
Longeveron Lomecel-B Data Selected For CHSS 51st Annual Meeting
09 Oct 2024 //
GLOBENEWSWIRE
Longeveron To Present At UBS Virtual Organ Restoration Day
07 Oct 2024 //
GLOBENEWSWIRE
Longeveron® Joins 3rd Annual ROTH Healthcare Conference
02 Oct 2024 //
GLOBENEWSWIRE
Longeveron To Attend Cell & Gene Meeting On The Mesa
26 Sep 2024 //
GLOBENEWSWIRE
Longeveron Announces Q2 2024 Financial Results And Business Update
14 Aug 2024 //
GLOBENEWSWIRE
Longeveron To Report Q2 2024 Results On August 14
05 Aug 2024 //
GLOBENEWSWIRE
FDA Grants Longeveron`s Lomecel-B RMAT Status For Mild Alzheimer`s
10 Jul 2024 //
GLOBENEWSWIRE
Longeveron® Announces Completion of Meeting forOn-going Pha2b Trial Lomecel-B™
11 Jun 2024 //
GLOBENEWSWIRE
Longeveron Announces CDMO Business, First Contract
03 Jun 2024 //
GLOBENEWSWIRE
Longeveron Announces Results from the CLEAR MIND Phase 2a Trial of Lomecel-B
20 Dec 2023 //
GLOBENEWSWIRE
Longeveron Announces Achievement of Surpassing 50% Enrollment in PII of Lomecel-B
11 Aug 2023 //
GLOBENEWSWIRE
Longeveron Announces New Long-Term Survival Data from ELPIS I Trial of Lomecel-B
09 May 2023 //
GLOBENEWSWIRE
Longeveron Announces Publication of Data from ELPIS I Trial of Lomecel-BTM
19 Jan 2023 //
GLOBENEWSWIRE
